Partnership will support the deployment of secure endpoint solutions across the Middle East and Africa (MEA) region ...
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) IMFINZI in combination with ...
Zacks.com on MSN
Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains?
Praxis Precision Medicines (PRAX) saw its shares surge in the last session with trading volume being higher than average. The ...
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...
Praxis Precision surges on positive ulixacaltamide data for essential tremor, but tolerability limits impact. Explore PRAX's ...
Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...
Topline results and additional data from the pivotal SynAIRgy and LunAIRo Phase 3 studies – the largest clinical program of an investigational ...
The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...
The Heathrow cyber disruption in September 2025 highlights how third-party vulnerabilities can ripple across national ...
Researchers warn of fileless payloads, memory hooks, and a UDP-based C2 controller that complicate detection and remediation.
Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results